Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 16.
doi: 10.1007/s15010-025-02608-7. Online ahead of print.

Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study

Andrea Marino #  1 , Alberto Enrico Maraolo #  2 , Maria Mazzitelli  3 , Alessandra Oliva  4 , Nicholas Geremia  5 , Andrea De Vito  6 , Chiara Gullotta  7 , Vincenzo Scaglione  3 , Eleonora Vania  3 , Sara Lo Menzo  3 , Paolo Navalesi  8   9 , Lorenzo Volpicelli  4 , Andrea Fiori  10 , Pamela Prestifilippo  11 , Annamaria Cattelan  3 , Claudio Maria Mastroianni  4 , Giordano Madeddu  6 , Bruno Cacopardo  7 , Giuseppe Nunnari  7
Affiliations

Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study

Andrea Marino et al. Infection. .
No abstract available

Keywords: Ceftazidime/avibactam; Enterobacetrales; ICU patients; KPC; Klebsiella pneumoniae; Meropenem/vaborbactam.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study was approved by the local Ethical Committees (no. 101/CECT2; no. 0069/2022 and 0341/2023). The study was conducted according to the guidelines of the Declaration of Helsinki. Consent for publication: Informed consent was waived due to the retrospective nature of the research. Competing interests: The authors declare no competing interests.

References

    1. Marino A, Pulvirenti S, Campanella E, Stracquadanio S, Ceccarelli M, Micali C, Tina LG, Di Dio G, Stefani S, Cacopardo B, et al. Ceftazidime-Avibactam treatment for Klebsiella Pneumoniae bacteremia in preterm infants in NICU: A clinical experience. Antibiot (Basel). 2023;12:1169. https://doi.org/10.3390/antibiotics12071169 . - DOI
    1. Tumbarello M, Raffaelli F, Giannella M, De Pascale G, Cascio A, De Rosa FG, Cattelan AM, Oliva A, Saracino A, Bassetti M, et al. Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study. Open Forum Infect Dis. 2024;11:ofae273. https://doi.org/10.1093/ofid/ofae273 . - DOI - PubMed - PMC
    1. Giacobbe DR, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, et al. Use of colistin in adult patients: A Cross-Sectional study. J Glob Antimicrob Resist. 2020;20:43–9. https://doi.org/10.1016/j.jgar.2019.06.009 . - DOI - PubMed
    1. Giacobbe DR, Marelli C, Cattardico G, Fanelli C, Signori A, Di Meco G, Di Pilato V, Mikulska M, Mazzitelli M, Cattelan AM, et al. Mortality in KPC-Producing Klebsiella Pneumoniae bloodstream infections: A changing landscape. J Antimicrob Chemother. 2023;78:2505–14. https://doi.org/10.1093/jac/dkad262 . - DOI - PubMed
    1. Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788. https://doi.org/10.1001/jama.2018.0438 . - DOI - PubMed - PMC

LinkOut - more resources